623 related articles for article (PubMed ID: 33795526)
1. Integrative radiogenomics analysis for predicting molecular features and survival in clear cell renal cell carcinoma.
Zeng H; Chen L; Wang M; Luo Y; Huang Y; Ma X
Aging (Albany NY); 2021 Mar; 13(7):9960-9975. PubMed ID: 33795526
[TBL] [Abstract][Full Text] [Related]
2. Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations.
Karlo CA; Di Paolo PL; Chaim J; Hakimi AA; Ostrovnaya I; Russo P; Hricak H; Motzer R; Hsieh JJ; Akin O
Radiology; 2014 Feb; 270(2):464-71. PubMed ID: 24029645
[TBL] [Abstract][Full Text] [Related]
3. Computed tomography-based radiomics prediction of CTLA4 expression and prognosis in clear cell renal cell carcinoma.
He H; Jin Z; Dai J; Wang H; Sun J; Xu D
Cancer Med; 2023 Mar; 12(6):7627-7638. PubMed ID: 36397666
[TBL] [Abstract][Full Text] [Related]
4. Differentiation of clear cell and non-clear cell renal cell carcinomas by all-relevant radiomics features from multiphase CT: a VHL mutation perspective.
Li ZC; Zhai G; Zhang J; Wang Z; Liu G; Wu GY; Liang D; Zheng H
Eur Radiol; 2019 Aug; 29(8):3996-4007. PubMed ID: 30523454
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a CT-based nomogram for preoperative prediction of clear cell renal cell carcinoma grades.
Zheng Z; Chen Z; Xie Y; Zhong Q; Xie W
Eur Radiol; 2021 Aug; 31(8):6078-6086. PubMed ID: 33515086
[TBL] [Abstract][Full Text] [Related]
6. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
Hsieh JJ; Chen D; Wang PI; Marker M; Redzematovic A; Chen YB; Selcuklu SD; Weinhold N; Bouvier N; Huberman KH; Bhanot U; Chevinsky MS; Patel P; Pinciroli P; Won HH; You D; Viale A; Lee W; Hakimi AA; Berger MF; Socci ND; Cheng EH; Knox J; Voss MH; Voi M; Motzer RJ
Eur Urol; 2017 Mar; 71(3):405-414. PubMed ID: 27751729
[TBL] [Abstract][Full Text] [Related]
7. Machine learning-based unenhanced CT texture analysis for predicting BAP1 mutation status of clear cell renal cell carcinomas.
Kocak B; Durmaz ES; Kaya OK; Kilickesmez O
Acta Radiol; 2020 Jun; 61(6):856-864. PubMed ID: 31635476
[TBL] [Abstract][Full Text] [Related]
8. Radiogenomics in Clear Cell Renal Cell Carcinoma: Machine Learning-Based High-Dimensional Quantitative CT Texture Analysis in Predicting PBRM1 Mutation Status.
Kocak B; Durmaz ES; Ates E; Ulusan MB
AJR Am J Roentgenol; 2019 Mar; 212(3):W55-W63. PubMed ID: 30601030
[TBL] [Abstract][Full Text] [Related]
9. A CT-based radiomics nomogram for differentiation of renal angiomyolipoma without visible fat from homogeneous clear cell renal cell carcinoma.
Nie P; Yang G; Wang Z; Yan L; Miao W; Hao D; Wu J; Zhao Y; Gong A; Cui J; Jia Y; Niu H
Eur Radiol; 2020 Feb; 30(2):1274-1284. PubMed ID: 31506816
[TBL] [Abstract][Full Text] [Related]
10. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
Brugarolas J
Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
[TBL] [Abstract][Full Text] [Related]
11. Differentiation of Clear Cell and Non-clear-cell Renal Cell Carcinoma through CT-based Radiomics Models and Nomogram.
Cheng D; Abudikeranmu Y; Tuerdi B
Curr Med Imaging; 2023; 19(9):1005-1017. PubMed ID: 36411581
[TBL] [Abstract][Full Text] [Related]
12. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
[TBL] [Abstract][Full Text] [Related]
13. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
14. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.
Kapur P; Peña-Llopis S; Christie A; Zhrebker L; Pavía-Jiménez A; Rathmell WK; Xie XJ; Brugarolas J
Lancet Oncol; 2013 Feb; 14(2):159-167. PubMed ID: 23333114
[TBL] [Abstract][Full Text] [Related]
15. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
Piva F; Santoni M; Matrana MR; Satti S; Giulietti M; Occhipinti G; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Principato G; Cascinu S; Montironi R
Expert Rev Mol Diagn; 2015; 15(9):1201-10. PubMed ID: 26166446
[TBL] [Abstract][Full Text] [Related]
16. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
Ibragimova I; Maradeo ME; Dulaimi E; Cairns P
Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518
[TBL] [Abstract][Full Text] [Related]
17. Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.
Tennenbaum DM; Manley BJ; Zabor E; Becerra MF; Carlo MI; Casuscelli J; Redzematovic A; Khan N; Arcila ME; Voss MH; Feldman DR; Motzer RJ; Benfante NE; Coleman JA; Russo P; Hsieh JJ; Hakimi AA
Urol Oncol; 2017 Aug; 35(8):532.e7-532.e13. PubMed ID: 28408295
[TBL] [Abstract][Full Text] [Related]
18. The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.
Liao L; Testa JR; Yang H
Cancer Genet; 2015 May; 208(5):206-14. PubMed ID: 25873528
[TBL] [Abstract][Full Text] [Related]
19. A radiogenomics biomarker based on immunological heterogeneity for non-invasive prognosis of renal clear cell carcinoma.
Gao J; Ye F; Han F; Jiang H; Zhang J
Front Immunol; 2022; 13():956679. PubMed ID: 36177018
[TBL] [Abstract][Full Text] [Related]
20. Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma.
Piva F; Giulietti M; Occhipinti G; Santoni M; Massari F; Sotte V; Iacovelli R; Burattini L; Santini D; Montironi R; Cascinu S; Principato G
Oncotarget; 2015 Oct; 6(31):32161-8. PubMed ID: 26452128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
